To address the current gaps in expert guidance related to the recent development and commercial availability of newer nonstatin agents, the American College of Cardiology published today an expert consensus decision pathway on the role of nonstatin therapies for LDL-C lowering in the management of atherosclerotic cardiovascular disease (ASCVD) risk reduction.